BDR Pharma launches generic version of Lenvatinib for cancer treatment in India
Lenvatinib is a molecule used to provide breakthrough therapy treatment for cancer patients.;
Advertisement
Mumbai: Drugmaker, BDR Pharmaceutical, has recently announced the launch of 4mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Lenvatinib is priced at INR 1620 (4 mg) and INR 2970 (10 mg) for a pack of 10 capsules.
Lenvatinib is a molecule used to provide breakthrough therapy treatment for cancer patients. The results of clinical trials conducted showed encouraging results with safety and efficacy on patients treated with aggressive tumors.
BDR Group focuses on development in 6 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, Dermatology and Women's Health which are its dream segment.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.